Global Custom Market Research Reports Provider Company

phone

XOMA Corp (XOMA) - Financial and Strategic SWOT Analysis Review

  • Published Date: 05 Jul 2018
  • Number of Pages: 51
  • Category: SWOT Analysis
  • Country: United States of America
XOMA Corp (XOMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

XOMA Corp (Xoma), formerly Xoma Ltd, is a biopharmaceutical company that develops antibody-based therapeutics. Its lead product, gevokizumab is a monoclonal antibody used for the treatment of a wide variety of inflammatory diseases and other diseases. Its other pipeline products include X358, X213 and X129. XOMA X358 is a human negative allosteric modulating insulin receptor antibody; X213 (formerly LFA 102) is an allosteric inhibitor of prolactin action; X129 is a potent fragment of a monoclonal antibody with negative allosteric modulation activity. Xoma has developed its proprietary antibody discovery, optimization and development technologies, comprising ADAPT, ModulX and OptimX. It operates through its subsidiaries in Bermuda, Ireland, and the US. Xoma is headquartered in Berkeley, California, the US.

XOMA Corp Key Recent Developments

Jun 26,2018: XOMA Added to the Russell 2000 and Russell 3000 Indexes
May 09,2018: XOMA Reports First Quarter 2018 Financial Results
May 08,2018: XOMA Announces $20 Million Credit Facility with Silicon Valley Bank to Advance Royalty-Aggregator Business Model
Mar 07,2018: XOMA Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
Jan 08,2018: XOMA Strengthens Leadership Team with Appointments of Chief Business Officer and General Counsel

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
Publisher Name : GlobalData


List of Tables 5
List of Figures 5
Section 1 - About the Company 6
XOMA Corp - Key Facts 6
XOMA Corp - Key Employees 7
XOMA Corp - Key Employee Biographies 8
XOMA Corp - Major Products and Services 9
XOMA Corp - History 10
XOMA Corp - Company Statement 14
XOMA Corp - Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Section 2 Company Analysis 17
Company Overview 17
XOMA Corp - Business Description 18
Geographical Segment: Asia Pacific 18
Performance 18
Geographical Segment: Europe 18
Performance 18
Geographical Segment: United States 19
Performance 19
XOMA Corp - Corporate Strategy 20
XOMA Corp - SWOT Analysis 21
SWOT Analysis - Overview 21
XOMA Corp - Strengths 21
XOMA Corp - Weaknesses 22
XOMA Corp - Opportunities 23
XOMA Corp - Threats 24
XOMA Corp - Key Competitors 25
Section 3 Company Financial Ratios 26
Financial Ratios - Capital Market Ratios 26
Financial Ratios - Annual Ratios 27
Performance Chart 29
Financial Performance 29
Financial Ratios - Interim Ratios 30
Financial Ratios - Ratio Charts 31
Section 4 Companys Lifesciences Financial Deals and Alliances 32
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 32
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 33
XOMA Corp, Recent Deals Summary 34
Section 5 Companys Recent Developments 35
Jun 26, 2018: XOMA Added to the Russell 2000 and Russell 3000 Indexes 35
May 09, 2018: XOMA Reports First Quarter 2018 Financial Results 36
May 08, 2018: XOMA Announces $20 Million Credit Facility with Silicon Valley Bank to Advance Royalty-Aggregator Business Model 37
Mar 07, 2018: XOMA Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update 38
Jan 08, 2018: XOMA Strengthens Leadership Team with Appointments of Chief Business Officer and General Counsel 40
Nov 06, 2017: XOMA Reports Third Quarter 2017 Financial Results 41
Aug 08, 2017: XOMA Reports Second Quarter 2017 Financial Results 42
May 18, 2017: XOMA Earns $10 Million Milestone Payment as Another of its Licensed Assets Advances into Clinical Development 43
May 09, 2017: XOMA Reports First Quarter 2017 Financial Results 44
Mar 16, 2017: XOMA Reports Fourth Quarter and Full Year 2016 Financial Results 45
Section 6 Appendix 47
Methodology 47
Ratio Definitions 47
About GlobalData 51
Contact Us 51
Disclaimer 51

List Of Tables

List of Tables
XOMA Corp, Key Facts 6
XOMA Corp, Key Employees 7
XOMA Corp, Key Employee Biographies 8
XOMA Corp, Major Products and Services 9
XOMA Corp, History 10
XOMA Corp, Subsidiaries 16
XOMA Corp, Key Competitors 25
XOMA Corp, Ratios based on current share price 26
XOMA Corp, Annual Ratios 27
XOMA Corp, Annual Ratios (Cont...1) 28
XOMA Corp, Interim Ratios 30
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 32
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 33
XOMA Corp, Recent Deals Summary 34
Currency Codes 47
Capital Market Ratios 47
Equity Ratios 48
Profitability Ratios 48
Cost Ratios 49
Liquidity Ratios 49
Leverage Ratios 50
Efficiency Ratios 50

List Of Figures

List of Figures
XOMA Corp, Performance Chart (2013 - 2017) 29
XOMA Corp, Ratio Charts 31
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 32
XOMA Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 33

XOMA Corp (XOMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData

View Report

XOMA Corp (Xoma), formerly Xoma Ltd, is a biopharmaceutical company that develops antibody-based therapeutics. Its lead product, gevokizumab is a monoclonal antibody used for the treatment of a wide variety

View Report

Synopsis TMC Texoma Medical Center Expansion Texas - Project Profile contains information on the scope of the project including project overview and location. The profile also details project ownership

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports